Get the Stockscreener App
14.55
1.49%
-0.22
Pre-market:
15.20
0.65
+4.47%
Zymeworks Inc. stock is traded at $14.55, with a volume of 362.73K.
It is down -1.49% in the last 24 hours and up +7.94% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$14.77
Open:
$14.67
24h Volume:
362.73K
Relative Volume:
0.78
Market Cap:
$1.00B
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
5.1964
EPS:
2.8
Net Cash Flow:
$-96.01M
1W Performance:
-15.46%
1M Performance:
+7.94%
6M Performance:
+62.03%
1Y Performance:
+74.04%
1-Day Range:
$14.43
$14.76
1-Week Range:
$14.43
$17.37
52-Week Range:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ZYME | 14.55 | 1.00B | 62.71M | -112.51M | -96.01M | 2.80 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Leerink Partners Upgrades Zymeworks (ZYME) - MSN
Redmile Group, LLC Adjusts Stake in Zymeworks Inc - GuruFocus.com
Zymeworks stock soars to 52-week high, hits $17.29 By Investing.com - Investing.com Australia
Zymeworks stock soars to 52-week high, hits $17.29 - Investing.com India
Zymeworks (NYSE:ZYME) Stock Rating Upgraded by Leerink Partners - Defense World
FY2024 EPS Estimates for Zymeworks Lifted by Leerink Partnrs - MarketBeat
Analysts Update Their Estimates For Zymeworks BC Inc - Stocks Register
Q4 Earnings Estimate for Zymeworks Issued By Leerink Partnrs - Defense World
Zymeworks (NYSE:ZYME) Raised to Strong-Buy at Leerink Partnrs - Defense World
Leerink Partnrs Forecasts Zymeworks' Q4 Earnings (NYSE:ZYME) - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking - Simply Wall St
Zymeworks (NYSE:ZYME) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Leerink lifts Zymeworks stock target on pipeline progress By Investing.com - Investing.com Nigeria
Leerink lifts Zymeworks stock target on pipeline progress - Investing.com
Zymeworks doses first subject in Phase I trial of ZW191 for solid tumours - Clinical Trials Arena
Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $18.00 - Defense World
Zymeworks Announces First Patient Dosed in Phase 1 Clinical - GlobeNewswire
Zymeworks Launches Phase 1 Trial for ZW191 - TipRanks
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - The Manila Times
Zymeworks (NYSE:ZYME) Sets New 52-Week High Following Analyst Upgrade - Defense World
Zymeworks stock soars to 52-week high of $14.08 amid robust gains - Investing.com Canada
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab (NASDAQ:ZYME) - Seeking Alpha
Zymeworks (NYSE:ZYME) Cut to Equal Weight at Wells Fargo & Company - Defense World
Zymeworks’ (ZYME) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Simply Wall St
Wells Fargo Downgrades Zymeworks (ZYME) - MSN
Zymeworks (NYSE:ZYME) Shares Gap Down – Here’s What Happened - Defense World
Zymeworks Inc. (NYSE:ZYME) Q3 2024 Earnings Call Transcript - Insider Monkey
Zymeworks Q4 2024 Earnings Preview - MSN
Zymeworks to Spotlight Innovations at Investor Conferences - MSN
Earnings call: Zymeworks reports Q3 2024 results and pipeline progress - Investing.com
Zymeworks (NYSE:ZYME) Shares Gap DownHere's Why - MarketBeat
Zymeworks stock downgraded at Wells Fargo (ZYME:NASDAQ) - Seeking Alpha
Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook - Simply Wall St
Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year - Yahoo Finance
HC Wainwright Reiterates Neutral Rating for Zymeworks (NYSE:ZYME) - MarketBeat
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Zymeworks Inc (ZYME) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Zymeworks Reports Q3 Results and Strategic Advances - TipRanks
Zymeworks Advances Biotherapeutic Pipeline in 2024 - TipRanks
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Zymeworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Zymeworks Q3 2024 Earnings Preview - MSN
Zymeworks Inc (ZYME) Q3 2024 Earnings Report Preview: What To Lo - GuruFocus.com
Zymeworks (NYSE:ZYME) PT Raised to $28.00 at Stifel Nicolaus - Defense World
Assenagon Asset Management S.A. Takes Position in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Zymeworks Announces Participation in Upcoming Investor Conferences - The Korea Bizwire
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):